TABLE 1.
Characteristics of included studies and patient population demographics.
| Studies: author, year published, study period, country | Study design | Group | Sample size | Age, years (mean ± SD) | Sex, no. female (%) | PELD/MELD at transplant (mean ± SD) | Diagnosis (no.) | IS regimen | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| aCholestatic | Metabolic | Malignancy | Viral hepatitis | ALF | Cryptogenic | AIH | Other | ||||||||
| Aydogdu et al, 2005, 1997–2003, Turkey29b | Retrospective | LDLT | 31 | 4 ± 3.6 | 13 (41.9%) | 27 ± 12.3 | 14 | 17 | 4 | 5 | 11 | 6 | 5 | Steroid + CNI | |
| DDLT | 30 | 11 ± 4.4 | 19 (63.3%) | 16 ± 13.3 | |||||||||||
| Oliveros et al., 2005, 1998–2005, Spain13 | Matched cohort | LDLT | 27 | 2.3 | 21 | 0 | 3 | 1 | 1 | 1 | |||||
| DDLT-whole | 8 | 2.8 | 14 | 6 | 2 | 1 | 3 | 1 | |||||||
| DDLT-partial | 19 | ||||||||||||||
| Bahador et al. 2009, 1999–2008 Iran57 | Retrospective | LDLT | 54 | 9.1 ± 5.6 | 19.2 ± 12.9 | 31 | 41 | 8 | 23 | 20 | Steroid + CNI + MMF | ||||
| DDLT-whole | 64 | ||||||||||||||
| DDLT-partial | 20 | ||||||||||||||
| Leung Chan et al, 2009, 1993–2008 Hong Kong30 | Retrospective | LDLT | 59 | 3.0 ± 3.8 | 26 (44%) | 20.8 ± 13.1 | 58 | 5 | 1 | 4 | 11 | Steroid + CNI | |||
| DDLT | 19 | 3.6 ± 3.9 | 11 (57.9%) | 18.3 ± 2.2 | |||||||||||
| Zhou et al, 2010, 1993–2009 China16 | Multicenter retrospective | LDLT | 208 | 118 | 125 | 23 | 7 | 14 | 5 | 3 | 24 | Steroid + CNI and MMF Steroid + CNI |
|||
| DDLT-whole | 72 | ||||||||||||||
| DDLT-partial | 46 | ||||||||||||||
| Darius et al, 2014, 1993–2010, Belgium14b | Retrospective | LDLT | 203 | 1.1 ± 2.3 | 95 (46.8%) | 153 | 12 | 21 | 2 | 15 | Steroid + CNI + Aza, Steroid + CNI, Basiliximab + CNI | ||||
| DDLT-whole | 88 | 3.3 ± 2.9 | 42 (47.7%) | 64 | 11 | 0 | 3 | 10 | |||||||
| DDLT-partial | 138 | 2.1 ± 2.9 | 65 (47.1%) | 93 | 11 | 6 | 18 | 10 | |||||||
| Tannuri et al, 2016, 1989–2014, Brazil58 | Retrospective | LDLT | 29 | 29 | |||||||||||
| DDLT-Whole | 10 | 50 | |||||||||||||
| DDLT-partial | 40 | ||||||||||||||
| Szymczak et al, 2018, 1990–2016, Poland59b | Retrospective | LDLT | 24 | 4 ± 3.7 | 16 (66.7%) | 27.3 ± 23.6 | 24 | ||||||||
| DDLT-whole | 31 | 36 ± 27.7 | 39 | ||||||||||||
| DDLT-partial | 8 | ||||||||||||||
| University of Alberta, 2018, 2005–2017, Canada | Retrospective | LDLT | 52 | 3.4 ± 4.2 | 25 (48.1%) | 12.5 ± 16.1 | 29 | 11 | 6 | 6 | |||||
| DDLT-whole | 29 | 6.6 ± 6.3 | 15 (51.7%) | 10.4 ± 12.9 | 17 | 6 | 1 | 2 | 2 | 1 | Basiliximab + CNI ± Steroid or MMF | ||||
| DDLT-partial | 29 | 3.3 ± 3.7 | 16 (55.2%) | 13.6 ± 13.5 | 20 | 5 | 3 | 1 | |||||||
| Montenovo, 2018, 2002–2016, USA15 | Multicenter retrospective | LDLT | 800 | 3.0 ± 4.7 | 408 (51%) | 17.2 ± 13.8 | 502 | 70 | 43 | 7 | 107 | 19 | 8 | 44 | |
| DDLT-whole | 3733 | 6.0 ± 6.1 | 1915 (51%) | 13.9 ± 14.5 | 1598 | 610 | 363 | 37 | 546 | 176 | 123 | 280 | |||
| DDLT-partial | 1784 | 2.6 ± 3.7 | 893 (50%) | 15.5 ± 14.9 | 924 | 237 | 183 | 4 | 263 | 66 | 17 | 90 | |||
| Kehar et al, 2019, 2000–2015, Canada9b | Retrospective | LDLT | 135 | 1.1 ± 2.9 | 64 (47.4%) | 10.7 ± 12.1 | 81 | 23 | 8 | 6 | 17 | CNI ± MMF or Sirolimus ± MMF | |||
| DDLT-whole | 76 | 4.7 ± 7.7 | 72 (45.6%) | 8.4 ± 11.4 | 55 | 29 | 12 | 35 | 27 | ||||||
| DDLT-Partial | 82 | ||||||||||||||
aBiliary atresia, Alagille’s syndrome, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis, Caroli disease.
bDenotes median to men conversion, calculated mean, or SD.
AIH, autoimmune hepatitis; ALF, acute liver failure; AZA, azathioprine; CNI, calcineurin inhibitor; DDLT, deceased donor liver transplantation; LDLT, living donor liver transplantation; MMF, mycophenolate mofetil; PELD, Pediatric End-stage Liver Disease.